Strategic Acquisition Isolere Bio is now part of Donaldson Company, a global filtration leader, which could enable cross-sell of downstream purification solutions and integrated bioprocessing workflows to Donaldson’s large enterprise customer base.

AAV and LV Focus Recent and ongoing development of IsoTag AAV, LV, AdV, and mRNA purification capabilities presents opportunities to target gene therapy and mRNA vaccine manufacturers seeking scalable, low-touchpoint purification options to alleviate bottlenecks.

Emerging Geographies With leadership changes and a growing team, there may be regional expansion opportunities in North America and Europe to expand customer reach, partnerships, and regional regulatory support for manufacturing solutions.

Academic and Collaborations Past collaborations with Oxford Biomedica and participation in major conferences like ASGCT signal receptivity to co-development and validation projects; potential to pursue new collaborations with gene therapy developers and contract manufacturers.

Evidence of Validation Manufacturing-grade IsoTag AAV reagent and validated production processes indicate credible regulatory and scale-up readiness, enabling targeted outreach to manufacturing sites seeking proven downstream solutions to reduce bottlenecks.